4594 Stock Overview
Engages in the development of cancer immunotherapy drugs in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BrightPath Biotherapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥44.00 |
| 52 Week High | JP¥99.00 |
| 52 Week Low | JP¥41.00 |
| Beta | 0 |
| 1 Month Change | -20.00% |
| 3 Month Change | -16.98% |
| 1 Year Change | -51.11% |
| 3 Year Change | -60.71% |
| 5 Year Change | -85.94% |
| Change since IPO | -89.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4594 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -4.3% | -2.5% | 0.5% |
| 1Y | -51.1% | 15.8% | 13.6% |
Return vs Industry: 4594 underperformed the JP Biotechs industry which returned 15.8% over the past year.
Return vs Market: 4594 underperformed the JP Market which returned 13.6% over the past year.
Price Volatility
| 4594 volatility | |
|---|---|
| 4594 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4594's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4594's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kenichi Nagai | www.brightpathbio.com |
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.
BrightPath Biotherapeutics Co., Ltd. Fundamentals Summary
| 4594 fundamental statistics | |
|---|---|
| Market cap | JP¥3.67b |
| Earnings (TTM) | -JP¥1.87b |
| Revenue (TTM) | JP¥262.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs 4594 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4594 income statement (TTM) | |
|---|---|
| Revenue | JP¥262.00m |
| Cost of Revenue | JP¥146.00m |
| Gross Profit | JP¥116.00m |
| Other Expenses | JP¥1.99b |
| Earnings | -JP¥1.87b |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4594 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:50 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2018/12/31 |
| Annual Earnings | 2018/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BrightPath Biotherapeutics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|